Cizzle Bio, Inc.

09/01/2026

New peer-reviewed research published in The Journal of Applied Laboratory Medicine supports the clinical utility of the CIZ1B biomarker for early lung cancer detection.

The study — led by Professor Dawn Coverley of the University of York — evaluated the same ELISA-based assay now commercially available to licensed healthcare providers in Dallas-Fort Worth and San Antonio. In the early-stage cohort, CIZ1B demonstrated 94% sensitivity and a 97% negative predictive value.

Read the press release: https://go.cizzlebio.com/5aPGDU

08/29/2026

The CIZ1B Biomarker Blood Test for Lung Cancer may provide licensed healthcare providers with an additional biomarker-based tool during lung cancer assessment.

Review clinician resources and ordering setup steps:
https://go.cizzlebio.com/pqkko2

08/27/2026

Cizzle Bio attended the Next Generation DX Summit 2026 in Washington, DC, where Dr. Lary Robinson of Moffitt Cancer Center presented on the potential of the CIZ1B biomarker to redefine early lung cancer detection.

Our post-event recap shares key takeaways from the presentation, including discussion of blood-based biomarkers, LDCT screening challenges, indeterminate pulmonary nodules, and the Moffitt Cancer Center clinical study evaluating CIZ1B.

Read the recap:
https://buff.ly/VvZc39w

Cizzle Bio recaps Dr. Lary Robinson’s Next Generation DX Summit 2026 presentation on CIZ1B, blood-based biomarkers, lung nodules, LDCT screening, and early lung cancer detection.

08/27/2026

Licensed healthcare providers can access CIZ1B Biomarker Blood Test clinician resources, including clinical information, patient considerations, and ordering setup steps.

Provider resources:
https://buff.ly/cMtGzCi

08/27/2026

Cizzle Bio was proud to participate in the 18th Annual Next Generation Dx Summit in Washington, DC.

Dr. Lary A. Robinson, director of the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center, presented "Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection" — examining how blood-based biomarkers may help clinicians evaluate indeterminate lung nodules and support earlier detection.

The CIZ1B Biomarker Blood Test is now available through licensed healthcare providers in Dallas-Fort Worth and San Antonio.

Read the full announcement: https://buff.ly/tMMQDb7

/PRNewswire/ -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced its participation in the...

08/25/2026

We were proud to attend the Next Generation DX Summit 2026 in Washington, D.C.

One of the highlights was a presentation by Dr. Lary Robinson, Director of the Lung Cancer Early Detection Center (LEAD) at Moffitt Cancer Center, on the potential of the CIZ1B biomarker blood test for early lung cancer detection.

Dr. Robinson also discussed the clinical validation study of the CIZ1B biomarker blood test currently underway at Moffitt Cancer Center.

It was wonderful to see Dr. Robinson and Cizzle Bio CEO Bill Behnke together following the presentation.

Detect Early. Save Lives.

08/21/2026

Cizzle Bio will attend the Next Generation DX Summit 2026, August 24–26 in Washington, DC — a leading conference for molecular diagnostics, precision medicine, and early cancer detection.

Featured presentation: "Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection" by Dr. Lary Robinson of Moffitt Cancer Center, Monday, August 24 at 11:15 AM EDT.

The CIZ1B Biomarker Blood Test for Lung Cancer is now available to licensed healthcare providers in Dallas-Fort Worth and San Antonio.

Read more: https://buff.ly/Nl7dBQW

08/20/2026

Healthcare providers in Dallas-Fort Worth and San Antonio can now review CIZ1B ordering setup steps.

The CIZ1B Biomarker Blood Test for Lung Cancer is designed to provide an additional lung cancer assessment alongside clinical judgment, imaging, patient history, risk factors, and other relevant information.

Review provider ordering setup steps:
https://buff.ly/p8wQOK8

08/13/2026

San Antonio, access to the CIZ1B Biomarker Blood Test for Lung Cancer is now available through licensed healthcare providers.

CIZ1B is a minimally invasive biomarker blood test designed to provide clinicians with an additional biomarker-based tool when evaluating patients for lung cancer.

The test is intended to complement established diagnostic approaches, including LDCT, and should be interpreted together with patient history, imaging studies, risk factors, symptoms, and other clinical findings.

For patients:
If you have concerns about your lung health or personal risk for lung cancer, speak with your healthcare provider about appropriate screening and diagnostic options and whether CIZ1B may be appropriate as part of your evaluation.

Patient information:
https://buff.ly/GuYec8X

For healthcare providers:
Clinical information, specimen collection guidance, patient resources, and ordering instructions are available through the Cizzle Bio clinician portal.

Clinician resources:
https://buff.ly/1zy9tqA

Detect Early. Save Lives.

08/11/2026

CIZ1B access is now available across the Dallas-Fort Worth metropolitan area, but the next step looks different for patients and healthcare providers.

For patients:
If you have concerns about your lung health or personal risk for lung cancer, start with a conversation with your healthcare provider. They can assess your individual risk, discuss appropriate screening and diagnostic options, and determine whether the CIZ1B Biomarker Blood Test may be appropriate as part of your clinical evaluation.

Patient information:
https://buff.ly/GuYec8X

For healthcare providers:
Clinical information, patient considerations, specimen collection guidance, and ordering resources for the CIZ1B Biomarker Blood Test are available through the Cizzle Bio clinician portal.

Clinician resources:
https://buff.ly/1zy9tqA

CIZ1B is a minimally invasive biomarker blood test designed to support earlier lung cancer detection and complement established diagnostic approaches, including LDCT.

Detect Early. Save Lives.